Search Results for “medical devices” – Page 41 – media

The Top 3 Digital Health Trends to Watch In 2018

Digital health broke out in 2017. We saw more investment than ever before: Over $4.7 billion flowed into a record number of companies. While these record-breaking investments underscore the enthusiasm for new digital health solutions, another revolution was quietly happening just outside the spotlight.
- Source: fortune
- 611
- December 21, 2017
digital health Researches Telemedicine
Check out these 6 simple Google tricks to streamline your search!

Google has become as much of a necessity to modern life as eating.Google’s search is a learning curve and odd one, too. WeYou use it every day, but very few of us actually use it to its full potential. With that being said, the search engine has plenty of tricks up its sleeve. If you want to streamline your search, it’s time to start implementing these 6 simple Google tricks.
- Source: Ddu
- 1,036
- December 15, 2017
Ddu College Google
FDA Approves Admelog, the First Short-acting “Follow-on” Insulin Product to Treat Diabetes

The U.S. Food and Drug Administration(FDA) approved Admelog (insulin lispro injection), a short-acting insulin indicated to improve control in blood sugar levels in adults and pediatric patients aged 3 years and older with type 1 diabetes mellitus and adults with type 2 diabetes mellitus. Admelog is the first short-acting insulin approved as a “follow-on” product (submitted through the agency’s 505(b)(2) pathway).
- Source: fda.gov
- 598
- December 13, 2017
Admelog blood sugar diabetes New Approvals
Gottlieb Announces More Regulatory Updates to Encourage Device Innovation

Less than a week after announcing 3 new guidance documents to streamline the review of digital health, the FDA is moving to refine its 510(k) medical device approval pathway.
- Source: hcanews
- 512
- December 12, 2017
digital health medical device Policy
FDA Announces 3 New Digital Health Policy Changes

FDA Commissioner Scott Gottlieb, MD, today announced 3 policy changes meant to encourage digital health innovation while modernizing the agency’s oversight of new tech.
- Source: hcanews
- 1,278
- December 8, 2017
digital health FDA innovation Policy
Novo Nordisk Receives FDA Approval of Ozempic (semaglutide) Injection For the Treatment of Adults with Type 2 Diabetes

Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) approved its New Drug Application (NDA) for OZEMPIC® (semaglutide) injection 0.5 mg or 1 mg, a once-weekly glucagon-like peptide (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.1 OZEMPIC® is administered once weekly, on the same day each week, and can be taken any time of the day, with or without meals.
- Source: medicalxpress
- 572
- December 6, 2017
diabetes FDA Novo Nordisk OZEMPIC®
FDA approves first treatment for certain patients with Erdheim-Chester Disease, a rare blood cancer

The U.S. Food and Drug Administration(FDA) has expanded the approval of Zelboraf (vemurafenib) to include the treatment of certain adult patients with Erdheim-Chester Disease (ECD), a rare cancer of the blood. Zelboraf is indicated to treat patients whose cancer cells have a specific genetic mutation known as BRAF V600. This is the first FDA-approved treatment for ECD.
- Source: Worldpharmanews
- 441
- November 8, 2017
BRAF V600 ECD FDA Zelboraf (vemurafenib)
Bristol-Myers, J&J sink cash into a new $95M European biotech fund

A venture capital firm in the Netherlands — backed by some big names in Big Pharma — has raised $95 million in a new fund to fuel European biotech startups.
- Source: Endpts
- 612
- November 3, 2017
diagnostics funding Market Views medical device therapeutics
Joining ICH–Opportunity or Challenge?

Ddu has gradually made its way through Europe by attending the CPhI Worldwide 2017 in Frankfurt and Medica 2017 in Düsseldorf, Germany. During conversations with manufacturers, ICH was frequently mentioned. Since China was admitted as one of the regulatory members of ICH in June of last year, it was now placed at the forefront of the discussions.
- Source: drugdu
- 724
- November 2, 2017
Ddu College EC FDA ICH MHLW PMDA
Ddu College–Market Report of Coronary Stents

Coronary heart disease is a common illness of cardiovascular disease which is treated mainly through medicines, coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI). Remarkably, PCI is preferable to both clinicians and patients for its short treatment course, small wound and significant therapeutic effects: doctors can use PCI to open coronary arteries that are narrowed or blocked by the buildup of atherosclerotic plaque without thoracotomy. Today, Ddu is going to share the market report of coronary stent with you.
- Source: Ddu
- 1,092
- October 27, 2017
cardiovascular coronary stent Ddu College

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.